A network-based drug prioritization and combination analysis for the MEK5/ERK5 pathway in breast cancer

Regan Odongo,Asuman Demiroglu-Zergeroglu,Tunahan Çakır

DOI: https://doi.org/10.1186/s13040-024-00357-1

2024-02-22

BioData Mining

Abstract:Prioritizing candidate drugs based on genome-wide expression data is an emerging approach in systems pharmacology due to its holistic perspective for preclinical drug evaluation. In the current study, a network-based approach was proposed and applied to prioritize plant polyphenols and identify potential drug combinations in breast cancer. We focused on MEK5/ERK5 signalling pathway genes, a recently identified potential drug target in cancer with roles spanning major carcinogenesis processes.

mathematical & computational biology

What problem does this paper attempt to address?

This paper aims to solve the problems of drug prioritization and combination analysis in the MEK5/ERK5 signaling pathway in breast cancer. Specifically, the researchers proposed a network - based method to evaluate the impact of plant polyphenols on the MEK5/ERK5 signaling pathway and identify potential drug combinations, in the hope of finding new drug targets and effective drug combination strategies in breast cancer treatment.

### Research Background
Complex diseases, such as cancer, are usually caused by systematic changes that affect multiple cellular processes. These changes can be detected at multiple levels of molecular organization, including changes in the expression levels of genes, proteins, and metabolites. These changes are currently used to identify drug targets and disease biomarkers. With the development of high - throughput molecular profiling techniques, such as transcriptomics, genome - wide molecular data can now be collected, and several studies have successfully used this data to link molecular changes to disease phenotypes. In particular, the expressed genes/proteins in these diseases form molecular networks that control specific cellular biological processes, thus providing a platform for the discovery of new drug targets, disease biomarkers, and biological mechanisms under disease conditions.

### Research Methods
1. **Data Acquisition**: Transcriptome data of breast cancer identified in previous studies were downloaded from the Gene Expression Omnibus (GEO) database, including 17 healthy control samples and 67 estrogen receptor - positive (ER+) patient samples.
2. **Differential Gene Expression Analysis**: The limma R package was used for differential gene expression analysis to identify differentially expressed genes between healthy control groups and ER+ breast cancer samples.
3. **Transcriptome Data of Plant Polyphenol - Treated**: Through GEO database search, all available transcriptome data sets of MCF - 7 cell models (an ER+ and PR+ breast cancer cell model) exposed to plant polyphenols were identified.
4. **Drug Signature Data**: LINCS1000 Connectivity Map data were downloaded from GEO, and gene fold - change data of MCF - 7 cell lines at different drug concentrations were extracted.
5. **Network Construction**: A human protein - protein interaction (PPI) data set of the BioGRID database was used to construct a PPI network related to the MEK5/ERK5 signaling pathway, and it was subdivided into more specific modules by the walktrap algorithm.
6. **Network Similarity Analysis**: The similarity between drug and disease target sub - networks was calculated through three indicators: network proximity, gene ontology similarity, and orthogonality score.

### Research Results
- **Prioritization of Plant Polyphenols**: Through a comprehensive analysis of network proximity, gene ontology similarity, and orthogonality score, the researchers gave priority to recommending genistein as a plant polyphenol.
- **Drug Combination Prediction**: Drug combination simulations predicted several FDA - approved breast cancer drugs with known pharmacological properties that can synergize with genistein to enhance the targeted network effect on the MEK5/ERK5 signaling pathway.

### Conclusion
This study proposed a computational framework for drug prioritization and combination analysis in the MEK5/ERK5 signaling pathway in breast cancer. This method is flexible and robust and can be applied to drug research in other complex diseases.

### Keywords
Network pharmacology, Transcriptome, Plant polyphenols, Breast cancer, MEK5/ERK5

### Formulas
1. **Network Proximity Calculation**:
\[
d(N_1, N_2)=1 - \frac{1}{|N_1|} \sum_{n_1 \in N_1} \min_{n_2 \in N_2} \frac{d(n_1, n_2)}{\text{Diam}(\text{network})}
\]
where \( d \) is the proximity score between two networks \( N_1 \) and \( N_2 \), and \(\text{Diam}(\text{network})\) is the diameter of the background network.

2. **Final Score**:
\[
\text{Final Score}(N_1, N_2)=d(N_1, N_2)+\tex